#Kabira trainslation trial#

We had a steep learning curve, building the company from a tiny start-up, through our initial public offering, and now to our phase 3 program. Ekaterina Malievskaia said, “I am grateful for the opportunity I had to co-found COMPASS Pathways and to work alongside such talented and dedicated people.

We are pleased that we will continue to benefit from her experience and insights as she remains on the board.”ĭr. We are closer to meaningful breakthroughs in care for patients thanks to her dedication, hard work and leadership. Her influence extends well beyond our company to the fields of psychedelic medicine and mental healthcare. COMPASS today reflects both the rigor and precision one would expect from a scientist and the compassion for and commitment to patients that one would expect from a physician. Kabir Nath, CEO, COMPASS Pathways, said, “Katya leaves an indelible mark on the company she helped found. She also developed the company’s psychological support model and built its network of trained therapists.

#Kabira trainslation trial#

During her tenure, she oversaw the development and execution of the groundbreaking phase 2b trial of COMP360 psilocybin for patients with treatment-resistant depression, started and helped build critical functions such as R&D, Digital Health, AI and Machine Learning, and Clinical Care Innovation.

She helped oversee the growth of COMPASS and provided critical executive leadership to the company both before and after its initial public offering in 2020. Together with George Goldsmith and Lars Wilde, Katya co-founded COMPASS Pathways in 2017, determined to bring much needed innovation to the field of mental health care. She will remain a member of the COMPASS Pathways Board of Directors, while her executive responsibilities will be carried forward by the existing executive team. Ekaterina Malievskaia will step down from her executive role effective June 16, 2023. LONDON, (GLOBE NEWSWIRE) - COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr.